Genetic Technologies Ltd
ASX:GTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Asuransi Bina Dana Arta Tbk PT
IDX:ABDA
|
ID |
|
S
|
Semapa Sociedade de Investimento e Gestao SGPS SA
ELI:SEM
|
PT |
|
C
|
Curanex Pharmaceuticals Inc
NASDAQ:CURX
|
US |
|
O
|
Obm Drilchem Tbk PT
IDX:OBMD
|
ID |
|
Channel Infrastructure NZ Ltd
NZX:CHI
|
NZ |
|
Gatekeeper Systems Inc
XTSX:GSI
|
CA |
|
Lam Research Corp
NASDAQ:LRCX
|
US |
|
Interface Inc
NASDAQ:TILE
|
US |
|
D
|
Distoken Acquisition Corp
NASDAQ:DIST
|
CN |
Genetic Technologies Ltd
PP&E Net
Genetic Technologies Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genetic Technologies Ltd
ASX:GTG
|
PP&E Net
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
PP&E Net
AU$2.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
43%
|
CAGR 10-Years
17%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
PP&E Net
AU$3.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
PP&E Net
AU$36.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
PP&E Net
AU$11.5m
|
CAGR 3-Years
76%
|
CAGR 5-Years
37%
|
CAGR 10-Years
24%
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
PP&E Net
AU$890.1k
|
CAGR 3-Years
82%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Genetic Technologies Ltd
Glance View
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.
See Also
What is Genetic Technologies Ltd's PP&E Net?
PP&E Net
0
AUD
Based on the financial report for Dec 31, 2024, Genetic Technologies Ltd's PP&E Net amounts to 0 AUD.
